Christopher I-Fu Li

Research Professor, Epidemiology



MD Medicine, University of California (San Francisco), 2000
PhD Epidemiology, University of Washington, 2003
MPH Epidemiology, University of Washington, 2000



Fred Hutchinson Cancer Research Center
Box 358080
1100 Fairview Ave N., M4-C308
P.O. 19024
Seattle, WA 98109
View Website »

Research Interests

Dr. Li is a cancer epidemiologist based at the Fred Hutchinson Cancer Research Center with research projects spanning cancer early detection/screening, etiology, and survivorship. He has significant expertise in cancer epidemiology and substantial experience in the design, leadership, and completion of multidisciplinary studies of cancer. Current research projects include: 1. A large population-based study of different molecular subtypes of breast cancer aimed at elucidating their risk factors and identifying novel subtype-specific tumor markers useful for predicting risk of disease recurrence (DOD Collaborative Innovator Award); 2. A nested case-control study of women with DCIS who did and did not go on to develop a second breast cancer aimed at developing novel epidemiologic, clinical, and molecular approaches for guiding clinical decision making for DCIS patients (R01); 3. Discovering and validating novel blood-based markers useful for the early detection of breast, colorectal, and ovarian cancers (U01); 4. Characterizing risk factors for second primary breast, lung, colorectal, and endometrial cancers among breast cancer survivors (R01); and 5. Discovering and validating novel biomarkers useful for assessing risk of recurrence among colorectal cancer survivors (R01 and U01). Selected leaderships activities include: 1. Serving as the co-PI of the Cancer Surveillance System (CSS), the Seattle-Puget Sound Surveillance, Epidemiology and End Results (SEER) cancer registry, 2. Chairing the DOD Breast Cancer Research Program’s Integration Panel (FY 2017), and 3. Co-chairing the 2017 AACR Conference on the Science of Cancer Health Disparities.

Recent Publications (PubMed)

Trajectories and risk factors of fatigue following colorectal cancer diagnosis.
(2023 Sep 12)
Colorectal Dis
Li X, Hoogland AI, Small BJ, Crowder SL, Gonzalez BD, Oswald LB, Sleight AG, Nguyen N, Lorona NC, Damerell V, Komrokji KR, Mooney K, Playdon MC, Ulrich CM, Li CI, Shibata D, Toriola AT, Ose J, Peoples AR, Siegel EM, Bower JE, Schneider M, Gigic B, Figueiredo JC, Jim HSL

Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas.
(2023 Sep 1)
Cancer Epidemiol Biomarkers Prev 32(9): 1146-1152
Yu M, Carter KT, Baker KK, Redman MW, Wang T, Vickers K, Li CI, Cohen SA, Krane M, Ose J, Gigic B, Figueiredo JC, Toriola AT, Siegel EM, Shibata D, Schneider M, Ulrich CM, Dzubinski LA, Schoen RE, Grady WM

Lessons to inform interventions to reduce racial and ethnic health disparities within hematologic malignancies.
(2023 Oct)
Cancer Causes Control 34(10): 883-886
Lin OM, Shen M, Li CI, Lee SJ

Associations of combined physical activity and body mass index groups with colorectal cancer survival outcomes.
(2023 Apr 3)
BMC Cancer 23(1): 300
Himbert C, Ose J, Gigic B, Viskochil R, Santuci K, Lin T, Ashworth A, Cohan JN, Scaife CL, Jedrzkiewicz J, Damerell V, Atkins KM, Gong J, Mutch MG, Bernadt C, Felder S, Sanchez J, Cohen SA, Krane MK, Hinkle N, Wood E, Peoples AR, Figueiredo JC, Toriola AT, Siegel EM, Li CI, Shibata D, Boucher K, Round JL, Ulrich AB, Schneider M, Huang LC, Hardikar S, Ulrich CM

Age-related differences in employment, insurance, and financial hardship among colorectal cancer patients: a report from the ColoCare Study.
(2023 Mar 23)
J Cancer Surviv
Berghuijs KMVT, Kaddas HK, Trujillo G, Rouhani G, Chevrier A, Ose J, Shibata D, Toriola AT, Figueiredo JC, Peoples AR, Li CI, Hardikar S, Siegel EM, Gigic B, Schneider M, Ulrich CM, Kirchhoff AC

Show complete publication list